Generic “Application Chain Integrity” Should Be Sponsor Focus, FDA Says
This article was originally published in The Pink Sheet Daily
ANDA sponsors should give FDA notice six months before they expect to launch, OGD Acting Director Uhl tells GPhA annual meeting.
You may also be interested in...
AMAG’s decision to fight US FDA’s decision to pull the preterm birth product seems unlikely to result in victory, but Makena will get to stay on the market during the appeal process, which is expected to be protracted and will likely include accusations that the agency is being insensitive to affected patients.
Pink Sheet reporters and editor discuss the future of coronavirus products with an emergency use authorization, potential pandemic-inspired regulatory changes at the FDA, and preview the agency’s upcoming advisory committee meeting on coronavirus vaccines.
‘Senator, please stop undermining confidence in a vaccine,’ Pence says when confronted with the accusation that the administration is politicizing the COVID vaccine development effort.